{"id":2055,"date":"2017-04-13T11:53:02","date_gmt":"2017-04-13T11:53:02","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2055"},"modified":"2021-07-24T12:56:44","modified_gmt":"2021-07-24T07:26:44","slug":"the-business-cocktail-18","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-18","title":{"rendered":"Cancer, diabetes and eczema on list; AbbVie&#8217;s Humira; Teva weighs $2B; Fresenius in buyout talks"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d0fa1d30669\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d0fa1d30669\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-18\/#Cancer_diabetes_and_eczema_star_in_2017_top-launch_list\" >Cancer, diabetes and eczema star in 2017 top-launch list<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-18\/#AbbVies_Humira_needs_a_discount_ICER_says_warning_Lilly_Sanofi_to_price_with_care\" >AbbVie&#8217;s Humira needs a discount, ICER says, warning Lilly, Sanofi to price with care<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-18\/#Debt-laden_Teva_looking_for_cash_weighs_2B_womens_health_sale\" >Debt-laden Teva, looking for cash, weighs $2B women&#8217;s health sale<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-18\/#Fresenius_in_buyout_talks_with_Akorn_in_bid_to_boost_sterile_injectables_unit\" >Fresenius in buyout talks with Akorn in bid to boost sterile injectables unit<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Cancer_diabetes_and_eczema_star_in_2017_top-launch_list\"><\/span>Cancer, diabetes and eczema star in 2017 top-launch list<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Launch prognostications are getting more attention than ever as they come out with \u201cDrugs to Watch\u201d list, and the highlights of different drugs shows what might work this year. By 2021, some of the drugs in the list are expected to bring in $16 billion, shared among Big Pharma and a few top biotechs. Some of the usual suspects are Roche\u2019s Ocrevus; Sanofi and Regeneron\u2019s Dupixent; AstraZeneca\u2019s durvalumab; Novo Nordisk\u2019s semaglutide; Tesaro\u2019s niraparib, just approved as Zejula; Novartis\u2019 LEE011, a.k.a. ribociclib, approved last month under the Kisqali brand name; and Kite Pharma\u2019s KTE-C19, which could be the first-ever CAR-T therapy for cancer. Dupixent, approved last month for moderate-to-severe atopic dermatitis (eczema), came in second with $2.8 billion.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"AbbVies_Humira_needs_a_discount_ICER_says_warning_Lilly_Sanofi_to_price_with_care\"><\/span>AbbVie&#8217;s Humira needs a discount, ICER says, warning Lilly, Sanofi to price with care<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">The best-selling drug in the world isn\u2019t worth its current price\u2014and isn\u2019t as good at its job as two of its potential competitors. That\u2019s the conclusion of the Institute for Clinical and Economic Review, a cost-effectiveness watchdog, which evaluated rheumatoid arthritis drugs and found AbbVie\u2019s Humira wanting. AbbVie takes issue with the assessment, and it\u2019s unlikely to have much impact on Humira\u2019s hefty sales, at least for now. It might, however, affect pricing decisions on forthcoming novel meds\u2014and the case for those novel meds with payers. It might also affect pricing on Humira biosimilars when they make their debut, and AbbVie\u2019s competitive stance when that happens. Overall, ICER found that immune-modulating RA drugs, from TNF-alpha inhibitors onward, work better than older therapies such as methotrexate. Pricing, however, earned a lower grade under quality-adjusted life year (QALY) analysis.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Debt-laden_Teva_looking_for_cash_weighs_2B_womens_health_sale\"><\/span>Debt-laden Teva, looking for cash, weighs $2B women&#8217;s health sale<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">In the wake of CEO Erez Vigodman\u2019s departure, Teva execs have been reviewing the company\u2019s business. And when it comes to what belongs on the chopping block, they may have reached their first conclusion. The company is weighing a sale of its women\u2019s health unit. The generics giant has brought on Morgan Stanley to help it find a buyer, and it\u2019s looking to start the sale process early next month, the news service said. Such a transaction could drum up about $2 billion, which could take a bite out of Teva\u2019s hefty debt load. Teva picked up the division from Merck KGaA\u2019s Merck Serono for \u20ac265 million in 2010. But a few years ago, the company put the kibosh on R&amp;D there to channel funds toward other projects, Globes notes.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Fresenius_in_buyout_talks_with_Akorn_in_bid_to_boost_sterile_injectables_unit\"><\/span>Fresenius in buyout talks with Akorn in bid to boost sterile injectables unit<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Growth in the generic sterile manufacturing industry has spawned a series of big buyouts in the last few years, and Germany\u2019s Fresenius is looking to M&amp;A to build its expertise with a potential deal for a U.S.-based player. Both Fresenius and Lake Forest, Illinois-based Akorn have confirmed they are in discussions, pointing out that there is no guarantee a deal will be finalized. Shares of Akorn closed up more than 18% at $29.77 on the news Friday and were up again today in premarket trading, pushing its market cap to $3.7 billion. Shares still remain far below the $56 a share at which they traded two years ago before accounting problems tied to its buyout of Hi-Tech Pharmacal and other producers gut-kicked its share price.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cancer, diabetes and eczema star in 2017 top-launch list Launch prognostications are getting more attention than ever as they come out with \u201cDrugs to Watch\u201d list, and the highlights of different drugs shows what might work this year. By 2021, some of the drugs in the list are expected to bring in $16 billion, shared [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1200,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[618,844,137,173,812,7517,900,760,845,843],"industry":[17225],"therapeutic_areas":[17237,17240,17228],"class_list":["post-2055","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-acquisitions","tag-biotech-firms","tag-cancer","tag-collaborations","tag-diabetes","tag-eczema","tag-humira","tag-mergers","tag-pharma-market","tag-sale","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Cancer, diabetes and eczema on list; AbbVie&#039;s Humira; Teva weighs $2B<\/title>\n<meta name=\"description\" content=\"Launch prognostications are getting more attention than ever as they come out with \u201cDrugs to Watch\u201d list and the highlights of different drugs...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-18\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cancer, diabetes and eczema on list; AbbVie&#039;s Humira; Teva weighs $2B\" \/>\n<meta property=\"og:description\" content=\"Launch prognostications are getting more attention than ever as they come out with \u201cDrugs to Watch\u201d list and the highlights of different drugs...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-18\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-04-13T11:53:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cancer, diabetes and eczema on list; AbbVie's Humira; Teva weighs $2B","description":"Launch prognostications are getting more attention than ever as they come out with \u201cDrugs to Watch\u201d list and the highlights of different drugs...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-18","og_locale":"en_US","og_type":"article","og_title":"Cancer, diabetes and eczema on list; AbbVie's Humira; Teva weighs $2B","og_description":"Launch prognostications are getting more attention than ever as they come out with \u201cDrugs to Watch\u201d list and the highlights of different drugs...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-18","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-04-13T11:53:02+00:00","article_modified_time":"2021-07-24T07:26:44+00:00","og_image":[{"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","width":1,"height":1,"type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-18","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-18","name":"Cancer, diabetes and eczema on list; AbbVie's Humira; Teva weighs $2B","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-18#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-18#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","datePublished":"2017-04-13T11:53:02+00:00","dateModified":"2021-07-24T07:26:44+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Launch prognostications are getting more attention than ever as they come out with \u201cDrugs to Watch\u201d list and the highlights of different drugs...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-18"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-18#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","caption":"Blue globes from drug capsule"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acquisitions<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">biotech firms<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">collaborations<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Diabetes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eczema<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Humira<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">mergers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">sale<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Acquisitions<\/span>","<span class=\"advgb-post-tax-term\">biotech firms<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">collaborations<\/span>","<span class=\"advgb-post-tax-term\">Diabetes<\/span>","<span class=\"advgb-post-tax-term\">Eczema<\/span>","<span class=\"advgb-post-tax-term\">Humira<\/span>","<span class=\"advgb-post-tax-term\">mergers<\/span>","<span class=\"advgb-post-tax-term\">pharma market<\/span>","<span class=\"advgb-post-tax-term\">sale<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Apr 13, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Apr 13, 2017 11:53 am","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"Blue globes from drug capsule","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2055"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2055\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1200"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2055"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2055"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2055"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2055"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}